Related Experiment Video

Updated: May 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

[Novel molecular-targeted drug for renal cancer(AXIS trial)]

Seiichiro Ozono1, Tatsuya Takayama

  • 1Dept. of Urology, Hamamatsu University School of Medicine, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 12, 2013
PubMed

Insights

Axitinib is a new tyrosine kinase inhibitor approved for advanced renal cell carcinoma after prior therapy failure. The AXIS trial demonstrated its efficacy in metastatic patients.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Advanced renal cell carcinoma (RCC) presents a significant clinical challenge.
  • Limited treatment options exist for patients with metastatic RCC who have progressed on prior systemic therapy.

Purpose:

  • To summarize the efficacy and safety of axitinib, a novel tyrosine kinase inhibitor.
  • To review the findings of the international, randomized, open-label AXIS trial.

Summary:

  • Axitinib demonstrated efficacy in patients with metastatic renal cell carcinoma who failed prior systemic treatment.
  • The AXIS trial provided robust data supporting axitinib's role in second-line therapy for advanced RCC.
  • Axitinib represents a new therapeutic option for refractory metastatic renal cell carcinoma.

Impact:

  • The approval of axitinib offers a new treatment avenue for patients with advanced renal cell carcinoma.
  • This advancement may improve outcomes for patients with limited therapeutic choices.
  • The AXIS trial data contribute valuable evidence to the management of metastatic RCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...